CLINICAL_TRIALS
trial_result
· 2011-12-22
Clinical Trial Update: A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects [Phase 1]
Summary
Phase 1 safety study evaluating a single vaginal dose of the P2G12 antibody in healthy female volunteers; the study has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Surrey | Conditions: Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED